Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan
Publication date: December 2026 Source: ESMO Real World Data and Digital Oncology, Volume 14 Author(s): K. Tamura, T. Tsujino, R. Taoka, K. Kobayashi, M. Miyake, K. Ogawa, Y. Sasaki, S. Tatarano, S. Katayama, M. Kato, H. Fukuhara, Y. Abe, Y. Oda, R. Minato, R. Shigehisa, R. Maenosono, M. Sugimoto, K. Shiraishi, K. Fujimoto, K. Wada
Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan. // ESMO Real World Data and Digital Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949820126001232?dgcid=rss_sd_all
Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan. ESMO Real World Data and Digital Oncology. https://www.sciencedirect.com/science/article/pii/S2949820126001232?dgcid=rss_sd_all
“Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan.” ESMO Real World Data and Digital Oncology.
@article{article44827,
title = {Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan},
journal = {ESMO Real World Data and Digital Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949820126001232?dgcid=rss_sd_all}
}